Sildenafil in Heart Failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: Rationale and design

European Journal of Heart Failure

Volumn 15, Issue 1, 2013, Pages 119-122

  Cooper, Trond J ^a   Guazzi, Marco ^b   Al Mohammad, Abdallah ^c   Amir, Offer ^d   Bengal, Tuvia ^e   Cleland, John G ^f   Dickstein, Kenneth ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF MILAN   (Italy)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d Heart Failure Center   (Israel)

^e RABIN MEDICAL CENTER   (Israel)

^f UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Heart failure; Pulmonary hypertension; Quality of life tools; Sildenafil; Symptoms

Indexed keywords

PHOSPHODIESTERASE V; SILDENAFIL;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; UNSPECIFIED SIDE EFFECT;

DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; QUALITY OF LIFE; QUESTIONNAIRES; STROKE VOLUME; SULFONES; TREATMENT OUTCOME;

EID: 84871220360     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs152     Document Type: Article

References (14)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guilelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
2. Blum A. Treating heart failure with sildenafil. Congest Heart Fail 2009;15: 181-1815.
3. Guazzi M, Casali M, Berti F, Rossoni G, D'Gennaro Colonna V, Guazzi MD. Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. Clin Pharmacol Ther 2007; 83:336-341.
4. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007;50: 2136-2144.
5. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004;44:2339-2348.
6. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011;4:8-17.
7. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007;116:1555-1562.
8. Borgdorff MAJ, Bartelds B, Dickinson MG, Boersma B, Weij M, Zandvoort A, Silljé HH, Steendijk P, de Vroomen M, Berger RM. Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. Eur J Heart Fail 2012;14:1067-1074.
9. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845-851.
10. Al-Hesayen A, Floras JS, Parker JD. The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. Eur J Heart Fail 2006;8:864-868.
11. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005;96:1436-1440.
12. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008;14:189-197.
13. Guazzi M, Vicenzi M, Arena R. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Fail 2012; 14:82-90.
14. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448.